AZD6793 + itraconazole

**AZD6793** is an investigational small molecule developed by AstraZeneca for the treatment of inflammatory diseases, including chronic obstructive pulmonary disease (COPD). It acts as an inhibitor of interleukin-1 receptor-associated kinase 4 (IRAK4), a key mediator in inflammatory signaling pathways. AZD6793 is currently in Phase I clinical trials and is administered orally, either as a suspension or tablet[1][2][5]. **Itraconazole** is a well-established triazole antifungal agent used to treat various systemic fungal infections such as aspergillosis, blastomycosis, and histoplasmosis. It inhibits fungal growth by blocking ergosterol synthesis through inhibition of 14-alpha demethylase. Itraconazole also has investigational uses in cancer therapy due to its ability to inhibit the hedgehog pathway[6][8]. The combination "AZD6793 + itraconazole" refers to their co-administration in clinical studies designed primarily to assess pharmacokinetic interactions between these two drugs[7].

Other names

ITZ